|
| 1 |
|
Conditions listed in this trial |
|
|
Galactosemia |
|
|
Premature Ovarian Failure |
|
| 2 |
|
Additional conditions recognized in this trial |
|
|
Galactosemias |
|
|
Ovarian Failure, Premature |
|
| 3 |
|
More general conditions related to this trial |
|
|
Adnexal Diseases |
|
|
Brain Diseases |
|
|
Brain Diseases, Metabolic |
|
|
Brain Diseases, Metabolic, Inborn |
|
|
Carbohydrate Metabolism, Inborn Errors |
|
|
Central Nervous System Diseases |
|
|
Endocrine System Diseases |
|
|
Genetic Diseases, Inborn |
|
|
Genital Diseases, Female |
|
|
Gonadal Disorders |
|
|
Metabolic Diseases |
|
|
Metabolism, Inborn Errors |
|
|
Nervous System Diseases |
|
|
Ovarian Diseases |
|
| 4 |
|
Interventions listed in this trial |
|
|
follitropin and lutropin |
|
| 5 |
|
Additional drug interventions recognized in this trial |
|
|
Follicle Stimulating Hormone |
|
| 6 |
|
More general drug interventions related to this trial |
|
|
Hormones |
|
|
Hormones, Hormone Substitutes, and Hormone Antagonists |
|
|
Pharmacologic Actions |
|
|
Physiological Effects of Drugs |
|
| 7 |
|
Sponsors listed in this trial |
|
|
Maastricht University Medical Center |
|
|
Galactosemie Vereniging Nederland (The Dutch Galactosemia Society) |
